Literature DB >> 21367981

A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Oliver Koeberling1, Isabel Delany, Dan M Granoff.   

Abstract

Native outer membrane vesicles (NOMV) (not detergent treated), which are prepared from recombinant strains with attenuated endotoxin activity and overexpressed factor H binding protein (fHbp), elicited broad serum bactericidal antibody responses in mice. The amount of overexpressed fHbp required for optimal immunogenicity is not known. In this study we prepared NOMV vaccines from LpxL1 knockout (ΔLpxL1) mutants with penta-acylated lipooligosaccharide and attenuated endotoxin activity. The recombinant strains had wild-type (1×) fHbp expression or were engineered for 3-fold- or 10-fold-increased fHbp expression (3× or 10× fHbp). Control vaccines included NOMV from ΔLpxL1/ΔfHbp mutants or recombinant fHbp. In mice, only the 10× fHbp NOMV vaccine elicited significantly higher serum IgG anti-fHbp antibody titers than the corresponding 1× fHbp NOMV or recombinant fHbp vaccine. The 10× fHbp NOMV vaccine also elicited higher bactericidal responses (P < 0.05) against five group B strains with heterologous PorA than the recombinant fHbp or 1× fHbp NOMV vaccine. The 3× fHbp NOMV vaccine gave higher bactericidal titers against only one strain. Serum bactericidal titers in mice immunized with the control ΔfHbp NOMV vaccines were <1:10, and bactericidal titers in mice immunized with the 10× fHbp NOMV vaccine were <1:10 after adsorption of anti-fHbp antibodies. Mixing antiserum to NOMV vaccines from fHbp knockout mutants with antiserum to recombinant fHbp did not increase anti-fHbp bactericidal titers. Thus, a critical threshold of increased fHbp expression is required for NOMV vaccines to elicit broad serum bactericidal responses, and the antibodies conferring protection are directed primarily at fHbp.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21367981      PMCID: PMC3122520          DOI: 10.1128/CVI.00542-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  48 in total

1.  Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998.

Authors:  C T Sacchi; A M Whitney; T Popovic; D S Beall; M W Reeves; B D Plikaytis; N E Rosenstein; B A Perkins; M L Tondella; L W Mayer
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

2.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

3.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

4.  Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity.

Authors:  P van der Ley; L Steeghs; H J Hamstra; J ten Hove; B Zomer; L van Alphen
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 5.  Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins.

Authors:  O Westphal; K Jann; K Himmelspach
Journal:  Prog Allergy       Date:  1983

6.  A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Emily M Braga; Qin Liu; Peter A Rice; Sanjay Ram; Dan M Granoff
Journal:  J Immunol       Date:  2011-02-16       Impact factor: 5.422

7.  Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine.

Authors:  Jo Anne Welsch; Raffaella Rossi; Maurizio Comanducci; Dan M Granoff
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.

Authors:  H J Jennings; C Lugowski
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

9.  Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development.

Authors:  Liana Steeghs; Jan Tommassen; Jeanette H W Leusen; Jan G J van de Winkel; Peter van der Ley
Journal:  J Endotoxin Res       Date:  2004

10.  Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.

Authors:  Vega Masignani; Maurizio Comanducci; Marzia Monica Giuliani; Stefania Bambini; Jeannette Adu-Bobie; Beatrice Arico; Brunella Brunelli; Alessandro Pieri; Laura Santini; Silvana Savino; Davide Serruto; David Litt; Simon Kroll; Jo Anne Welsch; Dan M Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  18 in total

1.  A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Authors:  Rolando Pajon; Carolyn M Buckwalter; Kay O Johswich; Scott D Gray-Owen; Dan M Granoff
Journal:  Vaccine       Date:  2015-02-04       Impact factor: 3.641

2.  Vaccines, reverse vaccinology, and bacterial pathogenesis.

Authors:  Isabel Delany; Rino Rappuoli; Kate L Seib
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

3.  Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Authors:  Oliver Koeberling; Anja Seubert; George Santos; Annalisa Colaprico; Mildred Ugozzoli; John Donnelly; Dan M Granoff
Journal:  Vaccine       Date:  2011-05-13       Impact factor: 3.641

4.  The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes.

Authors:  Holly Sanders; Carina Brehony; Martin C J Maiden; Caroline Vipond; Ian M Feavers
Journal:  Microbiology (Reading)       Date:  2012-01-12       Impact factor: 2.777

Review 5.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.

Authors:  Davide Serruto; Matthew J Bottomley; Sanjay Ram; Marzia M Giuliani; Rino Rappuoli
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641

6.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

7.  A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.

Authors:  Wildaliz Nieves; Hailey Petersen; Barbara M Judy; Carla A Blumentritt; Kasi Russell-Lodrigue; Chad J Roy; Alfredo G Torres; Lisa A Morici
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

8.  Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Authors:  Elizabeth E Moran; Robert Burden; Joseph E Labrie; Zhiyun Wen; Xin-Min Wang; Wendell D Zollinger; Lan Zhang; Valerian B Pinto
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

9.  Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.

Authors:  Eduardo Lujan; Rolando Pajon; Dan M Granoff
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

10.  HexR Controls Glucose-Responsive Genes and Central Carbon Metabolism in Neisseria meningitidis.

Authors:  Ana Antunes; Giacomo Golfieri; Francesca Ferlicca; Marzia M Giuliani; Vincenzo Scarlato; Isabel Delany
Journal:  J Bacteriol       Date:  2015-12-07       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.